Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Thymalin

Khavinson Thymic Peptide Complex

Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.

The entire human evidence base for Thymalin comes from Soviet and Russian institutions in the Khavinson lineage, principally the St. Petersburg Institute of Bioregulation and Gerontology, and has never been independently replicated to Western Phase 3 standard. The most cited results, a 6 to 8 year observational-controlled study in 266 elderly persons reporting reduced mortality with Thymalin and Epithalamin (Khavinson & Morozov, Neuro Endocrinol Lett 2003), are open-label, methodologically heterogeneous, Russian-language-dominant, and unreplicated, so the longevity and immune-restoration claims sit at the anecdotal/traditional level rather than confirmed RCT evidence.

FDA
Not approved (USA); subject of an FDA warning letter
WADA
Not listed on the WADA Prohibited List

Reference only. Not medical advice.

What can go wrong

All efficacy data is Russian and unreplicated; it is an undefined multi-peptide bovine thymus extract with no Western quality control, and it is sold in the West only as a research chemical.

Talk to a clinician before taking this. The Atlas can tell you what has been studied about Thymalin. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A bovine thymus-derived peptide complex developed in the 1970s by Vladimir Khavinson and Vyacheslav Morozov and part of the Russian bioregulator system, registered as a pharmaceutical in Russia for immune restoration. Nearly all efficacy data originates from Russian institutions in the Khavinson lineage and has not been independently replicated.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Immune restoration in aging
  • Longevity protocol (Khavinson)

How it is supposed to work

Thymalin is a complex of peptides extracted from the thymus, the gland that trains the immune system. It is used in the Russian bioregulator tradition to restore age-related decline in immune function, supporting the production and balance of T-cells. As an extract rather than a single defined molecule, its exact active components are not fully specified, which complicates any mechanistic claim.

Thymalin is not a single short peptide but a polypeptide complex extracted from the thymus, one of the original first-generation bioregulators. It is given as a short course of subcutaneous or intramuscular injections rather than continuously, and it sits alongside the synthetic two-amino-acid versions, Vilon and Thymogen, that came out of the same program.

Type
Thymus polypeptide complex
Target
Immune system
Use
Pulsed injection courses
Origin
St. Petersburg institute
Evidence
Russian clinical only
Western RCT
None

The Most-Studied Russian Immune Peptide, Still Only In Russia

Thymalin is the part of the Russian bioregulator story with the most actual clinical data behind it, and it is worth being precise about what that means. Russian trials, some described as large and long-running in elderly cohorts, have reported fewer respiratory infections and even lower mortality with repeated courses, which is a striking claim. The honest caveat is the same one that runs through this entire family: almost all of that evidence comes from the institute that developed it, over a single multi-decade research lineage, and it has not been independently replicated in blinded Western trials. So Thymalin is simultaneously the best-supported and still the unverified one. It is a real, decades-old preparation with provocative human data that the wider research world has never confirmed.

Safety in detail

On February 7, 2024 the FDA issued a warning letter to US Chem Labs for selling Thymalin as an unapproved and misbranded new drug; the FDA noted the product was marketed for uses including immunosuppression after chemotherapy and was offered for children, despite research-chemical labeling. There is no FDA-reviewed safety or purity standard for Thymalin sold in the United States.

  • Reported safety in decades of Russian clinical use is described as clean, with few serious adverse events, but that record comes largely from within the same research tradition that developed the peptides and has not been independently verified in Western trials.
  • Long-term safety in rigorous, controlled human studies is essentially uncharacterized outside that tradition.
  • Most material sold internationally is gray-market or supplement-grade, so unverified identity, dose and purity are the dominant practical risks.
  • Not FDA-approved for any use; claims of disease treatment are not supported by Western regulatory review.

Children and teenagers

Thymalin has no validated pediatric use outside specific historical Russian clinical contexts, and it is an unapproved injected preparation elsewhere. There is no appropriate over-the-counter pediatric use.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Thymalin reaches users through Russian pharmacies and the international gray market of bioregulator vendors and longevity clinics that sell the Khavinson line for organ-specific anti-aging. There is no approved Western product. The economy here is built on a striking but unreplicated evidence base.

How we got here

Thymalin is a Soviet-era thymus-extract immune bioregulator, a complex of short peptides isolated from the thymus glands of young calves. It was developed in the 1970s by Vladimir Khavinson and Vyacheslav Morozov within the Russian Military Medical Academy program on organ-specific bioregulators, and is registered as a pharmaceutical in Russia while its natural oral counterpart is sold as Vladonix. In the West it is available only as a research chemical, unapproved by the FDA or EMA.

Thymalin emerged from the Soviet thymic-peptide work that ran in parallel to Western thymosin research, and became one of the original bioregulators developed and studied for decades at the St. Petersburg institute, later joined by the synthetic immune dipeptides Vilon and Thymogen.

The numbers behind the grade

Type
Thymic peptide extract
Target
Immune system
Russia
Registered (Timalin)
FDA
Not approved
Evidence
Single-tradition
Western RCTs
None

The people taking it

The original thymic bioregulator and one of the most-cited compounds in the Khavinson literature, well known in longevity and immune-support circles.

Thymalin’s users are longevity enthusiasts and older adults drawn to immune support, the bioregulator-protocol community that runs pulsed organ-peptide courses, and patients in Russia where it has long been in clinical use.

Used mainly in Russia and among international longevity users as an immune-restoration bioregulator, by injection or as a supplement. Its standing rests on the Russian clinical tradition rather than independent Western evidence.

Set against the alternatives

Within its own family, Thymalin is the thymus and immune counterpart to Epithalon’s pineal focus, and the natural-extract predecessor to the synthetic immune dipeptides Vilon and Thymogen. Against a Western immune peptide like thymosin alpha-1, which is approved in dozens of countries and carries broader trial data, Thymalin is the parallel idea developed in near-isolation on a single research base. The shared lesson is that thymic-immune peptides are a real area of interest; the difference is how widely the evidence has been tested.

What we do not know

  • Whether independent, Western randomized trials confirm any of the claimed clinical effects.
  • Whether the proposed DNA-binding, gene-regulating mechanism actually operates in human tissue at the doses used.
  • Why, after forty years and hundreds of papers, replication outside the originating institute remains so limited.
  • Whether results from complex tissue extracts (Cytomaxes) translate to the defined synthetic peptides (Cytogens) sold alongside them.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Available internationally as oral or injectable bioregulator supplements (Cytogen and Cytomax lines) and as research-use-only peptide vials, with legal status varying by country. None is an FDA-approved medicine, so there is no regulated US prescription route; the honest course is to treat the claims with caution and consult a clinician.

Material reaches international buyers two ways: as branded Cytogen (synthetic) or Cytomax (animal-tissue extract) supplements produced in Russia, and as research-use-only vials, much of it synthesized in China. Neither route guarantees the identity or potency the label claims, so an independent certificate of analysis is the only real check and is uncommon.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Thymalin.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Supply chain. We have not mapped where it is made.
  • What could change. No forward-looking summary yet.

Sources

The studies that matter

  • Khavinson group longitudinal studies1980s-2010s

    Thymalin has the longest clinical investigational history of any compound in the bioregulator literature, with decades of studies on immune restoration and aging from the originating institute.

  • Independent replicationlimited

    A few outside groups have examined thymic peptide effects, but rigorous independent Western trials of Thymalin specifically have not been published.